Podcasts about Retinal

Join us for a first-look launch exclusive on Skin Anarchy as Dr. Ekta sits down with Keith O'Brien, the CEO of Hydrinity Accelerated Skin Science, to explore how regenerative medicine is transforming skincare. With a background in wound care, spine surgery, and oncology, Keith has applied the principles of rapid healing, pH balance, and inflammation control to aesthetics, creating products designed to repair, regenerate, and restore the skin.Hydrinity just launched their NEW RetaXome™ Daily Retinal Hydrator which is a proprietary, next-generation retinal-infused exosome that sets the new gold standard in regenerative retinoid therapy, offering high-dose, targeted delivery deep into the dermis — where it matters most.Hydrinity goes beyond facial care, addressing the unique needs of the body with formulas like the Encore Body Hydrator, which penetrates deeply with low molecular weight hyaluronic acid and high-dose antioxidants like Kakadu plum–derived vitamin C. Each product is designed with regenerative principles in mind: balancing pH, reducing inflammation, and supporting the skin's natural repair mechanisms.Science drives efficacy, but luxury isn't forgotten. Hydrinity formulations are clean, free from unnecessary dyes and fragrances, and crafted to feel as good as they perform.For Keith, consistency is key, and Hydrinity bridges the gap between biotech innovation and everyday beauty rituals. This episode offers a sneak peek into the future of skincare—where healing, science, and luxury intersect. Tune in to hear Keith O'Brien share the story behind Hydrinity, the science driving their formulations, and how regenerative medicine is reshaping both face and body care.To learn more about Hydrinity, visit their website and social mediaCHAPTERS:(0:02) Introduction & Guest Welcome(1:07) Hydrinity Origins & Wound Care Background(3:06) Expanding from Facial to Body Care(7:30) Scientific Principles: pH, Inflammation & Regenerative Medicine(11:20) Luxury Meets Science: Form, Function & Sensory Experience(16:11) Protocols, Estheticians & Evidence-Based Practice(19:01) Daily Habits & Importance of Body Skincare(21:18) New Product Launch: Hydrinity Retinol & Innovation(24:20) Retinol Therapy: Results, Stability & Gold StandardPlease fill out this survey to give us feedback on the show!Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.

Eyepoint CFO George Elston provides insights on the evolving space of retinal disease treatment, focusing on capital allocation, medical innovation, industry engagement and financial prudence.

We discuss the current state of the Good Days charitable foundation with Dr. Michael Lai, MD. PhD, Retina Group of Washington, Assistant Clinical Professor, Georgetown University School of Medicine

Claudia Muehlenweg helps people naturally improve their vision and ditch their glasses for good. She also explores how unresolved emotions can affect eyesight and healing.New episodes of Welcome to Wellness released every Friday!Not listening on Spotify? Show notes at: https://www.ashleydeeley.com/w2w/claudiaeyehealthEpisode brought to you by: ⁠⁠⁠⁠⁠⁠⁠⁠⁠ARAZA Beauty⁠Episode brought to you by:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ VieLight⁠⁠⁠ - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Code: DEELEY10Episode brought to you by:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Dry Farm Wines⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 07:36: Understanding Vision: The Role of Stress and Mindset11:21: Nutrition for Eye Health: The Power of Food12:55: The Importance of Eye Exams and Technology16:22: Surgery vs. Natural Vision Improvement22:43: Strengthening Vision Post-Surgery24:22: Practical Tips for Better Vision30:19: What Harms Our Eyes: Bad Habits and Practices31:17: Anxiety is related to myopia31:35: Anger is connected to farsightedness 31:58: Staring is awful for your eyes (make sure to blink!)32:32: The Impact of Blue Light on Vision36:39: Emotional Connections to Vision Problems43:07: Exploring Common Eye Diseases48:59: Cataract Surgery: Insights and Considerations51:36: Addressing Stargardt's Disease and Other Retinal Issues56:03: Encouraging Healthy Vision in Children57:06Aging and Vision: What You Need to KnowWhere to find Claudia:WebsiteLinkedInWhere to find Ashley Deeley:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Website⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠hello@ashleydeeley.com

What do retinal scans reveal about diabetes complications? In Part 2, Vinod Patel shares insights from his clinical research on diabetic retinopathy, including key risk factors, the impact of hypertension, and the future of screening using advanced imaging tools. A must-listen for clinicians and anyone curious about the eyes-diabetes connection.  Timestamps: 00:30 – Risk factors  02:17 – Drug treatments  03:01 – Retinal ischaemia   06:12 – Retinal imaging 

Ahead of her Kreissig Award Lecture at the Euretina Congress in Paris, Professor Maria Berrocal (Puerto Rico) joins Euretina past president Alistair Laidlaw to discuss why time-tested treatments like PRP and scleral buckling still matter. They explore the risks of over-reliance on anti-VEGF in proliferative diabetic retinopathy, the decline in buckle training, and how chandelier techniques could revive it

Retinoids get all the hype and all the confusion. In this episode, we break down exactly what estheticians need to know: the difference between retinoids, retinol, retinal (retinaldehyde), adapalene, and tretinoin, how they work in the skin, and when to reach for each one. We cover real-world use cases for acne, hyperpigmentation, and aging, how to start clients slow and steady without triggering irritation, SPF non-negotiables, Fitzpatrick considerations, and smart pairing (what to alternate, what to avoid, and how to “sandwich” for sensitive clients). If your clients are hearing TikTok takes and asking you for “the strongest one,” this gives you a clear, professional roadmap without overcomplicating their routines.Have an idea for an episode topic? Submit your ideas or questions: https://forms.gle/fZ5ocyGdTxoPVJBz5If you enjoy what you hear, don't forget to subscribe to Beauty Babble and rate our podcast. Your feedback helps us grow and continue delivering valuable insights to elevate your beauty industry journey. Stay tuned for more exciting episodes, and thank you for being a part of our Beauty Babble community!Follow Us:https://www.instagram.com/beautycultcanada/https://www.facebook.com/BeautyCultCanadahttps://www.linkedin.com/company/beauty-cult-canadahttps://www.youtube.com/channel/UCN-221KVEUvgYwqkDhTBZTA

Can a simple vitamin or supplement help protect your sight? In this Macular Chats episode, we explore what current science tells us about nutritional approaches to support eye health, particularly in the context of age-related changes in the retina. Join Dr. Brian McKay and Dr. Murray Brilliant for a conversation about the widely used AREDS2 nutrient formula, as well as exciting new research into L-DOPA, a naturally occurring compound that may offer a stronger role for maintaining retinal health.

Drs. Safa Rahmani and Sarwar Zahid join to discuss the July 2025 Retinal Physician focusing on surgical cases and pearls. Relevant Financial Disclosures: None

Drs. Armstrong and Patel discuss current and emerging therapies for diabetes-related macular edema and wet age-related macular degeneration including anti-VEGF agents, the need for durability and reduced treatment burden, alternative delivery strategies, novel molecules, and gene-therapy.

In this episode, Dr. Steve Vargo chats with Dr. James Wood to discuss the underutilized potential of retinal imaging in eye care practices. They explore how retinal imaging, particularly widefield and ultra-widefield imaging, can significantly enhance patient education, boost compliance, and improve financial outcomes for practices. Dr. Wood shares practical tips for obtaining clearer images and strategies for increasing patient acceptance of screening procedures. The conversation also delves into the future of retinal imaging technology and its role in addressing the growing needs of an aging population.   Follow our Podcast on All Available Platforms Follow our Podcast on Instagram Follow IDOC on Facebook Follow IDOC on LinkedIn Watch our Podcast Video on YouTube

Drs. Modi and Dedania discuss GLP-1 receptor agonists and the retinal patient, including how GLP-1 receptor agonists work, benefits and risks in patients with retinal disease, and data from retrospective studies.

Drs. Durga Borkar and Yashaswini Singh join host Dr. Jay Sridhar to discuss their recent publication regarding private equity (PE) acquisition and access to retinal detachment surgery. According to the study, physicians in PE-acquired practices decreased their number of retinal detachment repairs by nearly 20% after acquisition, potentially negatively impacting access to care and patient outcomes. Discussed in today's podcast: Singh Y, Cardenas GB, Torabzadeh H, Whaley CM, Borkar D. Private Equity-Owned Physician Practices Decreased Access To Retinal Detachment Surgery, 2014-22. Health Affairs. 2025 May;44(5):589-596. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Os contamos cómo realizamos paso a paso rutinas faciales de cara a los meses de verano, con tips y productos para cada tipo de piel y necesidad.LIMPIEZA: https://www.farmaelglobo.com/facial/3193-arturo-alba-manteca-de-primera-limpieza-y-desmaquillante-a-la-resina-de-pimenton-125ml-8437026064266.html?mot_tcid=4861bc8d-07c9-452b-8261-2b6662cfaa1c Aceite limpiador Mia Cosmetics: https://www.farmaelglobo.com/cosmetica/541-cornflower-cleansing-oil-100-ml-8436558889064.htmlMousse con extracto de algodón Farmacia el Globo: https://www.farmaelglobo.com/cosmetica/385-mousse-facial-con-extracto-de-algodon-farmacia-el-globo-8424561001665.html?mot_tcid=2dabffee-c1bc-44ca-86e9-e34715489135Espuma purificante: https://www.farmaelglobo.com/cosmetica/559-espuma-seborreguladora-farmacia-el-globo--8424561002938.htmlLimpiador exfoliante Glycoperfect: https://www.farmaelglobo.com/marcas/3528-endocare-renewal-glycoperfect-az-creamy-cleanser-1-tubo-150-ml-8436574363692.htmlTÓNICOS: -Piel resistente- Loción Arturo Alba: https://www.farmaelglobo.com/cosmetica/1893-arturo-alba-formula-locion-acida-exfoliante-global-125-ml-8437026064037.html?mot_tcid=e80e0a11-f499-41d5-bc83-e77fb28afe8a -Piel sensible- Loción Press and Glow: https://www.farmaelglobo.com/cosmetica/2376-medik8-press-and-glow-200-ml.html?mot_tcid=cac274bc-1abc-4253-b019-6f3aa2fc9a47-Piel deshidratadaEssence B3: https://www.farmaelglobo.com/cosmetica/1365-essence-b-150ml-3662361000944.htmlCONTORNO: Medik8 C tetra: https://www.farmaelglobo.com/cosmetica/2369-medik8-c-tetra-eye-contorno-de-ojos.html?mot_tcid=0b5a5cbf-c340-4c72-9ed3-151390fd9150HOLISI contorno: https://www.farmaelglobo.com/cosmetica/3342-holisi-dream-eye-contorno-de-noche-8437027826047.htmlSERUM DÍA: Vitamina C- Serum HOLISI: https://www.farmaelglobo.com/cosmetica/3179-holisi-daily-radiance-serum-vitamina-c-30-ml-8437027826009.html?mot_tcid=4f689340-04a3-4ea6-9783-2f57fd5c056fPiel sensible- Serum Skin Resist de Cantabria: https://www.farmaelglobo.com/marcas/3069-skin-resist-sensage-serum-1-envase-30-ml-8470002143050.html?mot_tcid=41c3203d-adec-41e2-90c9-c7348d50507b Piel acneica- Clarity Peptides Medik8: https://www.farmaelglobo.com/cosmetica/2375-medik8-clarity-peptides-30-ml.html?mot_tcid=38708e18-f585-4cab-8af6-17bafd7fc0aeRETINOIDES: Retinol inicio: https://www.farmaelglobo.com/cosmetica/1579-serum-absolut-retinol-5punto5-30-ml-8770198130927.htmlRetinol fuerte: https://www.farmaelglobo.com/cosmetica/1153-dr-arthouros-alba-crema-retexturizante-noche-retinol-puro-05-8437026064105.html?mot_tcid=098a6737-f64d-4bd4-a60c-1dfc4cc35877 Retinal dosis media: https://www.farmaelglobo.com/cosmetica/3181-holisi-the-retinal-treatment-serum-retinal-noche-30-ml-8437027826016.html?mot_tcid=954d9eea-0a76-4f06-a98f-80faf9b22d7f MANCHAS: Fading Treatment de HOLISI: https://www.farmaelglobo.com/cosmetica/3180-holisi-the-fading-treatment-serum-despigmentante-30-ml-8437027826023.html?mot_tcid=b566c795-f224-45e1-bef2-3e88c19e59adEN CASO DE FIRMEZA: https://www.farmaelglobo.com/cosmetica/1912-singuladerm-xpert-collageneur-serum-50-ml-8436564666772.htmlSERUM CON GLICÓLICO: https://www.farmaelglobo.com/cosmetica/3527-endocare-renewal-glycolic-intensive-serum-1-envase-50-ml-8470002117075.htmlPROTECCIÓN SOLAR:Radiant silk (acabado satinado): https://www.farmaelglobo.com/cosmetica/3565-holisi-radiant-silk-50-spf-crema-proteccion-solar-8437027826061.htmlPrimaderm advance light: https://www.farmaelglobo.com/cosmetica/2933-singuladerm-xpertsun-urban-advanced-light-textur-8436564667076.html TRATAMIENTO SEMANAL: Paté exfoliante: https://www.farmaelglobo.com/cosmetica/3043-arturo-alba-pate-exfoliante-fisico-renovador-50g-8437026064136.html?mot_tcid=e46bc43c-b94e-4742-a74b-b0d8f6d0e3deMascarilla hidratante con pantenol y ácido hialurónico: https://www.farmaelglobo.com/marcas/3464-mary-and-may-hialuronico-y-pantenol-mascarilla-30-uds-8809670681524.html

We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, George Magrath, CEO of Opus Genetics, shares with Host, Erin Harris, how the company is advancing gene therapies for inherited retinal diseases (IRDs), with a focus on LCA5, a rare and severe form of childhood blindness. Built on the foundational science of Dr. Jean Bennett and leveraging the legacy of Luxturna, Magrath shares how Opus is developing subretinal AAV-based therapies targeting seven distinct mutations. He also explains why gene therapy is particularly well-suited to IRDs, shares compelling early clinical data, and discusses the promise of early intervention in preserving vision and enabling proper neural development. Subscribe to the podcast!Apple | Spotify | YouTube

Pravin Dugel, CEO of Ocular Therapeutix provides insights into existing treatments and future product candidates for retinal diseases, underlining the unique challenges, opportunities and innovations in this evolving landscape. www.ocutx.comPravin U. Dugel, MD Biography

Drs. Akshay Thomas and Sarwar Zahid join for a journal club podcast discussion of three recent high-impact articles:Visual Fields in Diabetic Retinopathy (https://www.ophthalmologyretina.org/article/S2468-6530(25)00208-8/abstract)Gender Differences in Case Volume (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2833393)Private Equity Practices and Retinal Detachment Volume (https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2024.01204?journalCode=hlthaff)Relevant Financial Disclosures: NoneYou can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

One of the challenges of delivering gene therapies to the eye is that once a subretinal injection is made, the therapy's distribution is confined to the margins of the pocket of fluid that is created, known as a bleb. Atsena, which is developing gene therapies for X-linked retinoschisis and Leber congenital amaurosis 1, uses its AAV.SPR technology that allows the gene therapy to spread laterally after injection. We spoke to Patrick Ritschel, CEO of Atsena Therapeutics, about the challenges of gene therapies for inherited retinal diseases, how the company's unique vector technology addresses this, and how it allows for safer and more effective delivery of gene therapies to the retina.

Unlock the fascinating connection between your eyes and your brain in this episode! Did you know that your retina can reveal early signs of brain disease—even years before symptoms appear? Discover how the eye, formed from brain tissue, acts as a window into your neurological and circulatory health. We'll dive into new research showing that simple eye exams may one day predict aging and age-related diseases like macular degeneration, diabetic retinopathy, hypertension, multiple sclerosis, Parkinson's, and even Alzheimer's.You'll learn about the role of the optic nerve, the latest breakthroughs in retinal imaging, and how changes in the eye might signal Alzheimer's up to 8–9 years before a diagnosis. Plus, we'll discuss why prevention—through diet, exercise, and targeted supplements—is more important than ever for protecting both your mind and vision.Ready to nourish your brain and eyes? Here's our recommended list of essential nutrients:Taurine, lutein, zeaxanthin, mesozeaxanthin, B vitamins, bilberry, ginkgo biloba, omega-3 fatty acids, alpha-lipoic acid, N-acetylcysteine, glutathione, bacopa, lycopene, selenium, zinc, and the mushroom lion's mane.Stay informed and take charge of your health—tune in and visit us at naturaleyecare.com for the latest tips on protecting your eyes and brain!

Today, we are joined by the esteemed Dr. Jay Chhablani, a distinguished professor of ophthalmology and vitreoretinal surgeon at the Department of Ophthalmology, University of Pittsburgh. As the Director of Clinical Research at the UPMC Vision Institute, Dr. Chhablani stands at the forefront of cutting-edge advancements in eye care. Embark on a fascinating exploration as Dr. Chhablani, a retina specialist and surgeon, shares his wealth of knowledge on retinal diseases, ranging from bothersome floaters to age-related macular degeneration. Delve into the intricacies of ophthalmic surgeries, including the delicate art of retinal detachment repair. Press play to discover: The origins and prevention of eye floaters, along with effective treatment approaches. Conditions warranting surgical intervention for floaters. Navigating through complications associated with common ophthalmic surgeries and procedures. Distinguishing between the two primary forms of macular degeneration. The mechanics of novel drug therapies in slowing the progression of retinal diseases. Eager to learn more? Tune in and explore more at Jay Chhablani, MD | Department of Ophthalmology | University of Pittsburgh. Episode also available on Apple Podcasts: apple.co/30PvU9C

Dr. Nadia Khalil and Dr. Jean Bouchart discuss the diagnostic approach to intracerebral hemorrhage, the causes of cerebral small vessel disease, and the interpretation of biomolecular tests.  Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209796 

Drs. Ramsudha Narala, Kat Talcott, and Sarwar Zahid join to preview the June 2025 edition of Retinal Physician, focusing on GLP-1RAs and diabetic retinopathy, DRCR.net trial updates, CRAO protocol implementation, and early career advice for attendings. Relevant Financial Disclosures: None

Dr. Nadia Khalil talks with Dr. Jean Bouchart about the diagnostic approach to intracerebral hemorrhage, the causes of cerebral small vessel disease, and the interpretation of biomolecular tests.  Read the related article in Neurology® Resident & Fellow Section.  Disclosures can be found at Neurology.org. 

In this episode of the BroadEye Podcast, hosts Shawn Maloney and Dr. Bruno Fernandes welcome Prof. Michel Michaelides, one of the most active clinical researchers in ophthalmology today. Prof. Michaelides leads a large inherited retinal disease clinic—seeing 30–40 children and adults each week—and splits her time between patient care, advanced imaging research, and steering more than ten ongoing clinical trials.   Why This Matters Inherited retinal diseases affect hundreds of thousands worldwide, and for most there is still no approved treatment. Over the past two years, we've seen multiple Phase 1/2 gene-therapy trials move into registrational studies, alongside novel antioxidant approaches and AI-driven biomarkers. Today's conversation cuts through the jargon to give you a clear picture of where the field stands—and where it's headed.   Key Takeaways Beyond RPE65: While Luxturna paved the way, newer AAV-based therapies for X-linked RP (RPGR) and other targets are now in Phase 2 and Phase 3 trials, with early data showing promising safety and efficacy. Imaging & Function: Prof. Michaelides is pioneering next-generation retinal imaging devices and novel functional assays to capture meaningful changes in vision—critical for shortening trial timelines. Antioxidant Strategies: High-dose N-acetylcysteine trials are under way, offering a non-viral approach to slow photoreceptor degeneration across multiple genetic subtypes. AI in Stratification: Machine-learning algorithms on retinal scans can help predict progression rate and identify the best candidates for specific therapies, improving both trial design and patient outcomes. Balancing Dose & Safety: Finding the sweet spot between transgene expression and immune activation remains a core challenge—Prof. Michaelides shares lessons learned from dose-escalation cohorts. Phase 3 & Beyond: With over a hundred patients enrolled in pivotal studies, we're closing in on potential approvals—but long-term follow-up and real-world evidence will determine ultimate impact.   About the Guest Prof. Michelle Michaelides is a clinician-scientist specializing in inherited retinal diseases. She leads dedicated adult and pediatric IRD clinics, oversees the development of advanced imaging and functional biomarkers, and serves as principal investigator on over ten clinical trials spanning gene therapies, antioxidant agents, and AI-guided stratification tools. Prof. Michaelides regularly lectures at international conferences and collaborates with industry and academic partners to accelerate the translation of research into real-world treatments.

In this latest episode of the BroadEye podcast, hosts Shawn Maloney and Dr. Bruno Fernandes sit down with Dr. Arshad M. Khanani, MD, MA, FASRS, a pioneer in vitreoretinal gene-therapy trials and Managing Partner at Sierra Eye Associates. Dr. Khanani shares front-line insights into how genetic medicines are reshaping treatment for inherited and degenerative retinal diseases, highlighting both the promise and the practical challenges of bringing one-time therapies to patients.   Why Gene Therapy Matters Today Recent years have seen the first US approvals of in-vivo retinal gene therapies, beginning with voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophy in December 2017. These one-off treatments offer durable vision improvements where none existed before, but they also raise questions of long-term safety, vector delivery, and equitable access.   Dr. Khanani's Journey With over a decade leading surgical trials in sustained-delivery and viral-vector therapies, Dr. Khanani has overseen early human work on next-generation agents—including subretinal injections of AAV vectors and novel capsid designs. He describes lessons learned from Phase 1 safety studies through global registrational trials, emphasizing iterative “vector evolution” to boost efficacy and minimize inflammation.   Key Takeaways Vector Optimization: Directed-evolution platforms are accelerating discovery of capsids that target photoreceptors more precisely, reducing off-target toxicity. Durability vs. Dose: Striking the right balance between transgene expression and immune activation remains central—higher doses don't always equal better outcomes. Regulatory Pathways: While Luxturna set a precedent, streamlined FDA and EMA guidance on trial endpoints and real-world evidence will shape the next wave of approvals. Cost & Access: Innovative payment models (e.g., outcomes-based installment plans) are emerging to address the multi-hundred-thousand-dollar price tags of these therapies.   About the Guest Dr. Arshad M. Khanani, MD, MA, FASRS, is a vitreoretinal surgeon, researcher, and Managing Partner at Sierra Eye Associates in Reno, Nevada. He holds dual degrees in medicine and medical humanities from the University of Nevada, Reno, and is a fellow of the American Society of Retina Specialists. Dr. Khanani has authored over 100 peer-reviewed articles on retinal disease and served as principal investigator on more than 30 clinical trials of gene and cell therapies for inherited and age-related retinal disorders. He also lectures internationally on surgical innovation, vector design, and the economics of advanced ocular treatments.

2521 Advancing Treatments for Inherited Retinal Diseases (May 21, 2025) Show Notes Research is key to fighting blinding eye diseases. Hosts Nancy and Peter Torpey talk with Jason Menzo, CEO of the Foundation Fighting Blindness, about advancing treatments for inherited retinal diseases, funding research initiatives, and launching new mental health resources to support individuals with … Continue reading 2521 Advancing Treatments for Inherited Retinal Diseases (May 21, 2025) →

Interview with researcher Levi Todd, PhD.

Drs. Akshay Thomas and Sarwar Zahid join to preview the May 2025 edition of Retinal Physician, focusing on future developments in stem cells, microbots, artificial intelligence, and more.Relevant Financial Disclosures: None

In this episode of Medsider Radio, we sat down with Vicky Demas, CEO of identifeye HEALTH (formerly Tesseract Health), who's leading the company's efforts to democratize access to retinal imaging. Using advanced algorithms and automated systems, identifeye's technology captures and analyzes retinal images to detect early signs of disease.Before joining identifeye HEALTH, Vicky led new product development at GRAIL, supporting the creation of the company's multi-cancer early detection test (Galleri). She was also a founding member of Google Life Sciences (later Verily) within Google [x], where she led teams focused on diagnostics, medical devices, and translational laboratory science. An engineer and scientist, Vicky holds over 20 patents and has authored numerous scientific publications across multiple disciplines.In this interview, Vicky challenges founders to consider: Are you building a diagnostic solution that can scale globally or a product limited to specialized healthcare settings? She also discusses why understanding real-world implementation challenges early can prevent costly missteps later.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Vicky Demas.

BUFFALO, NY — April 14, 2025 — A new #research paper was #published in Aging (Aging-US) Volume 17, Issue 3, on March 4, 2025, titled “Deciphering age-related transcriptomic changes in the mouse retinal pigment epithelium.” The study, led by first authors Sushil K. Dubey and Rashmi Dubey with corresponding author Mark E. Kleinman from East Tennessee State University, reveals that aging causes inflammation, oxidative stress, and gene disruption in the retinal pigment epithelium (RPE), a vital layer of cells in the eye. These changes may explain why older adults are more vulnerable to age-related eye diseases. The researchers also developed a human cell model to study retinal aging and test future therapies. The RPE plays a key role in maintaining retinal health. It recycles light-sensitive molecules, supports the visual cycle, and protects the retina from damage. When this layer becomes damaged, vision problems such as age-related macular degeneration can develop. In this study, researchers compared gene activity in RPE cells from young and aged mice. They found that aging increased the activity of genes involved in immune system responses, inflammation, and oxidative stress, three known triggers of tissue damage. At the same time, genes related to vision and light detection became less active, weakening the RPE's ability to support healthy vision. To reinforce these findings, the research team also aged human RPE cells in the lab. Over time, these cells showed the same patterns: inflammation increased, while genes tied to visual function decreased. This human cell model offers a practical way to explore how RPE degeneration happens over time and how it might be slowed down or reversed. The research also identified “hub genes,” which are central players of the gene networks involved in RPE aging. These are connected to immune signaling, oxidative damage, and changes in the eye's structural support. Many of these genes are already known to be involved in age-related retinal degeneration, so they may become important targets for future treatments aimed at protecting vision in older adults. “GO annotation of downregulated genes included processes related to visual perception, sensory perception of light stimulus, detection of light stimulus, detection of visible light, detection of external stimulus, detection of abiotic stimulus, phototransduction, cellular response to interferon-beta, response to interferon-beta, and response to light stimulus.” By mapping how the RPE changes with age at the molecular level, this study provides a clearer understanding of why aging leads to eye disease. It also introduces a reliable laboratory model that researchers can use to test new therapies. Altogether, the work is a key step toward developing treatments to slow or prevent vision loss tied to retinal aging. Read the full paper: DOI: https://doi.org/10.18632/aging.206219 Corresponding author: Mark E. Kleinman- kleinman@etsu.edu Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords: aging, transcriptome, retinal pigment epithelium, oxidative stress, inflammation, chronological aging To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

Drs. Kovacs and Starr join for the latest gimmick the retina world is going wild for: how do you manage this retinal detachment scenario?Relevant Financial Disclosures: NoneYou can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Hearing the buzz around skin cycling? We have been too. This week, we're joined by Dr. Whitney Bowe as she breaks down the concept of skin cycling. Listen in as she discusses her treatment philosophy, what it means for skin routines to be "smarter not more," and offers valuable advice for curious dermatologists looking to challenge conventional wisdom. Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com. Whitney Bowe, MD is a renowned, board-certified dermatologist and scientist based in New York. She is one of the most in-demand dermatologists in the country, in addition to being a founding member of the Dermstore Medical Advisory Board and a distinguished thought leader in the space. For the past seven years, her practice has been fully booked and capped, but now with her skin-care line, Dr. Whitney Bowe Beauty, you can bring the doctor home with you. Dr. Bowe championed a focus on the skin-gut-mind connection. Her “three-dimensional” approach to skincare—treating skin from both the outside and inside—challenged long-held beliefs within the field of dermatology. She is also responsible for bringing the viral skin-care concept of Skin Cycling to the world, which has amassed more than 3 billion TikTok views. With a deep knowledge of the skin, skin care products and dermatology, Dr. Bowe is constantly quoted in top media outlets like Vogue, The New York Times and Good Morning America. Enjoy 15% off your Dr. Whitney Bowe Beauty order at drwhitneybowebeauty.com with code LEARNSKIN15, valid April 3-17, 2025. Don't miss out!      

Drs. Akshay Thomas and Priya Vakharia join to preview the April 2025 edition of Retinal Physician, focusing on current and future therapies for neovascular AMD.Relevant Financial Disclosures: Dr. Sridhar has consulted for Genentech, Regeneron, and Eyepoint. Dr. Vakharia has consulted for Regeneron, Ocular Therapeutix, and Eyepoint.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, Host Erin Harris dives into the world of retinal gene therapy with Kenji Fujita, M.D., Chief Medical Officer of Atsena Therapeutics. Atsena develops treatments for inherited retinal diseases, including X-linked retinoschisis (XLRS), a rare genetic condition that currently has no FDA-approved therapy. They talk through the impact of XLRS on patients, the challenges of gene delivery to the retina, and how Atsena's AAV vector technology is designed to overcome these hurdles. They also discuss the significance of the Fast Track designation recently granted to Atsena's XLRS program, the role of patient advocacy in rare disease research, and the key milestones to watch for in the months ahead.Subscribe to the podcast!Apple | Spotify | YouTube

Which of the two following findings would be anticipated in the normal fundoscopic exam of a healthy 40-year-old woman who is normotensive, generally in good health and without ocular complaint?  A. Arteriovenous nickingB. Optic cup to disc ratio < .0.5C. Retinal arteries are brighter and narrower than veins  D. Slight bulging of the optic diskVisit fhea.com to learn more!

Drs. Rebecca Soares, Akshay Thomas, and Sarwar Zahid join the podcast for a journal club discussion covering three recent articles in major ophthalmology journals.Macula-Off Retinal Detachment Prognostic Factors (https://journals.lww.com/retinajournal/abstract/9900/preoperative_and_early_postoperative_factors.944.aspx)Progression to PDR from NPDR after Cataract Surgery (https://www.aaojournal.org/article/S0161-6420(25)00125-3/abstract)Sexual Harassment in Ophthalmology (https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2830480)Relevant Financial Disclosures: NoneYou can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Ogul Uner, MD, invites Scott Oliver, MD, to the podcast to review a case of a 60-year-old man who presented with new flashes, floaters, and blurriness in his inferior field of vision in his right eye. The patient is a high myope with a relative afferent pupillary defect and pigmented cells in the anterior vitreous, with OCT imaging showing a macula-off retinal detachment. Dr. Oliver shares his approach to this case, reviews risk factors for retinal detachments, and shares insights into treatment.

Drs. Katherine Talcott and Akshay Thomas join to discuss the March 2025 edition of Retinal Physician focusing on dry age-related macular degeneration, including photobiomodulation, complement inhibition, and deep learning for imaging.Relevant Financial Disclosures: Dr. Sridhar has consulted for Apellis.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/DJG865. CME credit will be available until March 3, 2026.Retinal Disease in Emergency Medicine: Timely Recognition and Referral for Specialty CareThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com Early detection of Alzheimer's disease is crucial, and accessible diagnostic tools like retinal imaging are becoming increasingly vital.  In this episode, Eliav Shaked, co-founder of RetiSpec, discusses their innovative approach to early and accurate Alzheimer's detection using retinal imaging and artificial intelligence. RetiSpec focuses on identifying the core pathology of Alzheimer's, specifically amyloid burden, through a simple eye examination that can be incorporated into annual checkups. The company is also working on other neurodegenerative diseases beyond Alzheimer's. Eliav emphasizes the significance of recent breakthroughs in Alzheimer's medication, highlighting the potential of disease-modifying drugs now available, along with the growing innovation and therapeutic development in the space. He also predicts that more drugs will be developed for earlier stages of the disease and that technology will revolutionize healthcare.  Tune in and learn how this innovative technology is paving the way for better Alzheimer's care! Resources:  Connect and follow Eliav Shaked on LinkedIn. Follow RetiSpec on LinkedIn and visit their website.  Fast Track Your Business Growth: Outcomes Rocket is a full-service marketing agency focused on helping healthcare organizations like yours maximize your impact and accelerate growth. Learn more at outcomesrocket.com

How do couples navigate the tumultuous journey of unexpected medical crises? For Wayne and Ivanna, it began with Wayne's emergency retina surgery, quickly followed by Ivanna's shocking breast cancer diagnosis at age 33. They found solace and strength in each other, embracing health advocacy and community support. Through their ordeal, they transformed their challenges into a mission to inspire and educate others. Key Questions Answered 1. What health advocacy steps does Ivanna recommend for women? 2. How did Ivanna and Wayne handle the emotional and mental health aspects of dealing with illness? 3. How did Ivanna's initial breast cancer diagnosis occur, and what was her reaction? 4. What was Wayne's role and response in supporting Ivanna during her health challenges? 5. How did Ivanna and Wayne's health challenges affect their family plans and vacations? 6. What critical health decision did Ivanna make regarding her cancer treatment, and what was the outcome? 7. What was the significance of self-advocacy as highlighted by both Ivanna and the host Dorothy Gibbons? Timestamped Overview 00:00 Met beautiful woman while bartending one Sunday. 03:43 Date night mishap: fancy wine, no glassware. 08:17 Breast lump concerns repeatedly dismissed by doctors. 10:14 Got biopsy results earlier than expected. 13:10 Struggled with pregnancy and potential health issues. 16:29 Post-pregnancy breast changes important for diagnosis. 21:41 Seeking definitive guidance on radiation treatment necessity. 25:20 Concerned about children's fast-paced upbringing. 27:53 Vacation plan canceled due to emergency surgery. 29:49 Retinal detachment diagnosed; emergency surgery needed. 33:43 Not ready for breast cancer survivor group.See omnystudio.com/listener for privacy information.

Imagine a future where a simple photo of your eye can detect chronic diseases like diabetes and heart conditions!  In this episode, Vicky Demas, CEO of identifeye HEALTH, shares how her company is using AI and automation to revolutionize diagnostic imaging. Discover how identifeye HEALTH is tackling workflow inefficiencies, improving access to care, and enabling early detection of chronic diseases like diabetes and cardiovascular conditions.  Tune in to explore the future of personalized medicine and patient-centered healthcare!

Drs. Safa Rahmani and Sarwar Zahid join the podcast to preview the January 2025 edition of Retinal Physician, found online at http://www.retinalphysician.com.Relevant Financial Disclosures: Dr. Sridhar has consulted for Genentech and Regeneron.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi